ev3, Inc. (EVVV) benefits from the growing demand for minimally invasive treatment of vascular diseases and disorders. Vascular disease and its precursors affect over 90 million people in the United States and more than 1 billion people worldwide. Vascular disease is the leading cause of death in the world.
The company’s broad product portfolio makes it well positioned for long-term growth. In addition, ev3’s products are primarily life-sustaining, a hedge against the current economic turmoil. We rate the company’s stock an Outperform with a target price of $13.Zacks Investment Research
